RT Journal Article SR Electronic T1 Genetic analysis of functional rare germline variants across 9 cancer types from the DiscovEHR study JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2019.12.09.19013334 DO 10.1101/2019.12.09.19013334 A1 Manu Shivakumar A1 Jason E. Miller A1 Venkata Ramesh Dasari A1 David Carey A1 Radhika Gogoi A1 Dokyoon Kim A1 on behalf of the DiscovEHR collaboration YR 2019 UL http://medrxiv.org/content/early/2019/12/12/2019.12.09.19013334.abstract AB Rare variants play an essential role in the etiology of cancer and characterizing rare germline variants that impact the risk of cancer is an ongoing challenge. We performed a genome-wide rare variant analysis using germline whole exome sequencing (WES) data derived from the Geisinger MyCode initiative to discover cancer predisposition variants. The case-control association analysis was conducted by binning pathogenic and likely pathogenic variants in 5,538 cancer patients and 7,286 matched controls in a discovery set and 1,991 cancer patients and 2,504 matched controls in a validation set across nine cancer types. We discovered 87 genes and 106 pathways significantly associated with cancer (Bonferroni-corrected P < 0.05) out of which seven genes and 26 pathways replicated from the validation set (suggestive threshold P < 0.05). Further, four genes and 21 pathways were discovered to be associated with multiple cancers (Bonferroni-corrected P < 0.05). Additionally, we identified 13 genes and two pathways associated with survival outcome across seven cancers (Bonferroni-corrected P < 0.05), where two genes, PCDHB8 and DCHS2, were also associated with survival outcome in TCGA data. In summary, we conducted one of the largest pan-cancer association studies using germline data derived from a single hospital system to find novel predisposition genes and pathways associated with nine cancers. Our results can inform future guidelines for germline genetic testing in cancer, which will be helpful in screening for cancer high-risk patients. This work adds to the knowledge base and progress being made in precision medicine.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by NLM R01 NL012535. This project was also funded, in part, under a grant with the Pennsylvania Department of Health (#SAP 4100070267). The Department specifically disclaims responsibility for any analyses, interpretations or conclusions. We gratefully acknowledge the funding support from Geisinger Medical Center (SRC-075) (RG) and Rice Women’s Cancer Research Fund (RG and VRD). Support for this work was also provided by NHGRI T32HG009495-01 (JEM). The funders specifically disclaim responsibility for the study design, data collection, analyses, interpretation, conclusions, and writing of the manuscript.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe summary data supporting the conclusions of this manuscript will be made available by the authors to any qualified researcher subject to a data use agreement.